Program: Education Program
Session: Have We Optimized Therapy Yet for Patients with AML?
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, Clinical Research, Chemotherapy, Combination therapy, drug development, Diseases, Therapies, therapy sequence, Myeloid Malignancies
Session: Have We Optimized Therapy Yet for Patients with AML?
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, Clinical Research, Chemotherapy, Combination therapy, drug development, Diseases, Therapies, therapy sequence, Myeloid Malignancies
Sunday, December 10, 2023, 4:30 PM-5:45 PM
Disclosures: Watts: Rafael Pharma: Consultancy; Reven Pharma: Consultancy; Daiichi Sankyo: Consultancy; Celgene/BMS: Consultancy; Servier: Consultancy; Rigel: Consultancy, Research Funding; Aptose: Consultancy; Immune Systems Key, Ltd.: Research Funding; Takeda: Consultancy, Research Funding; Attivare: Consultancy.
OffLabel Disclosure: I will discuss approved indications and ongoing clinical trials, this may also off-label use of approved therapies when given in combination with each other
<< Previous Presentation
|
Next Presentation